Kenvue (NYSE:KVUE) Releases Quarterly Earnings Results

Kenvue (NYSE:KVUE) announced its quarterly earnings data on Tuesday. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03, Briefing.com reports. The company had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The business’s revenue for the quarter was down 24.9% compared to the same quarter last year. Kenvue updated its FY24 guidance to $1.10-$1.20 EPS.

Kenvue Stock Up 1.2 %

KVUE traded up $0.24 during trading hours on Wednesday, hitting $20.32. 13,368,911 shares of the company’s stock were exchanged, compared to its average volume of 17,001,166. The stock’s 50-day moving average is $19.85 and its two-hundred day moving average is $20.11. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. Kenvue has a 1-year low of $17.82 and a 1-year high of $27.80.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Tuesday, May 7th. This represents a $0.80 annualized dividend and a dividend yield of 3.94%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Sanford C. Bernstein started coverage on Kenvue in a report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price target on the stock. JPMorgan Chase & Co. cut their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 9th. Royal Bank of Canada decreased their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. William Blair initiated coverage on Kenvue in a research report on Wednesday, April 3rd. They issued a “market perform” rating for the company. Finally, The Goldman Sachs Group started coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average target price of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.